Highlights Newsletter 1 This newsletter presents you the following key sessions: Watch the video interview with Prof. dr. H. Wildiers about the treatment of early stage breast cancer in older adults PERTAIN study: Pertuzumab in combination with trastuzumab and an aromatase inhibitor significantly prolongs progression-free survival Fulvestrant most effective in patients without visceral metastases OncoGambit provides an online personalized treatment recommendation to patients based on tumor stage and molecular biomarkers The addition of everolimus to fulvestrant improves outcomes for postmenopausal patients with HR-positive, HER2-negative metastatic breast cancer BROCADE study: adding the PARP inhibitor veliparib to chemotherapy significantly improves overall response rate in BRCA mutant breast cancer